WHAT IS MISDIRECTION? Critiquing “Antineoplastons: Has the FDA kept its promise to the American people ?”

March 29, 1996
�
Then United States Food and Drug Administration Commissioner, David Kessler told the American people:
�
1. We will eliminate unnecessary paperwork … that used to delay or discourage … cancer research … by non-commercial clinical investigators
�
2. The … FDA’s initiatives … will allow …the agency … to rely on smaller trials … fewer patients … if there is evidence … of partial response in clinical trials
�
I don’t want to get into any particular … agent … except let me point out … that … the information needs to be part … of clinical trials
�
3. We will accept … less information … up front –
�
4. we’re going to require further study AFTER … approval … because the science … has matured
�
5. The important – point … is that information needs to be gathered … through scientific means … through clinical – trials … and I think – that’s … that’s very important uhh very … important point
�
You can’t … just … use an agent here – or there … you have to use it … as part of a clinical trial … so we can get information … on whether the drug works
�
6. The uhh agency has … many … trials … has has approved trials … for patients … with antineoplastons
�
7. We are committed to providing expanded access … availability … for American patients for any drug … there’s reason to believe … may work
——————————————————————
BOTTOM LINE:
——————————————————————
Everything else is MISDIRECTION
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/22/antineoplastons-has-the-fda-kept-its-promise-to-the-american-people
——————————————————————
A. What is the FDA’s definition of “unnecessary paperwork”?
�
B. What is the FDA’s definition of “smaller trials”?
�
C. What is the FDA’s definition of “fewer patients”?
�
D. What is the FDA’s definition of “evidence … of partial response“?
�
E. What is the FDA’s definition of “less information … up front”?
�
F. What is the FDA’s definition of “we’re going to require further study AFTER … approval”?
�
G. What is the FDA’s definition of “We are committed to providing expanded access … availability … for American patients for any drug … there’s reason to believe … may work”?
======================================
2003 – 2009 Phase II preliminary
——————————————————————
2003 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101
(Drugs in R and D / Drugs in Research and Development)
�
2003: Protocol – recurrent diffuse intrinsic brain stem glioma
�
12 – Patients Accrued
10 – Evaluable Patients
�
2 / 20% – # and % of Patients Showing Complete Response
3 / 30% – # and % of Patients Showing Partial Response
3 / 30% – # and % of Patients Showing Stable Disease
2 / 20% – # and % of Patients Showing Progressive Disease
======================================
http://www.burzynskiclinic.com/scientific-publications.html
Interim Reports on Clinial Trials:
�
1. 10/2003
�
NEURO-ONCOLOGY
�
Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I.
�
Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive MULTICENTRIC GLIOMA
�
A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/970.pdf
Neuro-Oncology. 2003; 5: 358
Volume 5 Issue 4 October 2003
�
10/2003 – Protocol – MULTICENTRIC GLIOMA
�
12 – Children Patients Accrued
10 – Evaluable Patients
(9 months-17 years / 9 – median age)
�
4 / 33% – # and % of Patients Showing Complete Response
2 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
1 / 9% – # and % of Patients Nonevaluable due to only 4 weeks of treatment / lack of follow-up scans
======================================
Interim Reports on Clinial Trials:
�
16. 2003
�
DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)
�
BT-11
BRAIN STEM GLIOMA
�
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA:
�
a preliminary report.
http://www.ncbi.nlm.nih.gov/pubmed/12718563
Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M.
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
�
Pgs. 91-92 and 95
�
3/1996 – Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled / Pg. 94)
�
12 – Patients Accrued (6 males / 6 females)
(4-29 years / 10 – median age)
10 – Evaluable Patients
�
2 / 20% – # and % of Patients Showing Complete Response
3 / 30% – # and % of Patients Showing Partial Response
3 / 30% – # and % of Patients Showing Stable Disease
2 / 20% – # and % of Patients Showing Progressive Disease
======================================
2004 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26
(Drugs in R and D / Drugs in Research and Development)
�
2004: Protocol – incurable recurrent and progressive multicentric glioma
�
12 – Patients Accrued
(9 – median age)
11 – Evaluable Patients
�
4 / 33% – # and % of Patients Showing Complete Response
3 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:
�
2. 10/2004
�
NEURO-ONCOLOGY
�
BT-20
Patients With GLIOBLASTOMA MULTIFORME (GBM)
�
Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V.
�
Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent GLIOBLASTOMA MULTIFORME
http://www.burzynskiclinic.com/images/stories/Publications/1218.pdf
Neuro-Oncology. 2004; 6: 384
Volume 6 Issue 4 October 2004
Abstracts from the Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004
�
Pg. 385
�
10/2004 – Protocol – glioblastoma multiforme (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy
�
22 – Evaluable Patients
(6 men / 16 women / 27-63 /47 – median age)
�
1 / 4.5% – # and % of Patients Showing Complete Response
1 / 4.5% – # and % of Patients Showing Partial Response
12 / 54.5% – # and % of Patients Showing Stable Disease
8 / 36.5% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:
�
3. 10/2004 (DBSG)
�
NEURO-ONCOLOGY
�
Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.
�
Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic BRAIN STEM GLIOMA
http://www.burzynskiclinic.com/images/stories/Publications/1219.pdf
Neuro-Oncology. 2004; 6: 386
Volume 6 Issue 4 October 2004
�
60 patients
(31 didn’t meet admission criteria to the study and were treated under Special Exception (SE))
�
10/2004 – Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG)
�
29 – Evaluable Patients
�
7 / 24% – # and % of Patients Showing Complete Response
6 / 21% – # and % of Patients Showing Partial Response
6 / 21% – # and % of Patients Showing Stable Disease
10 / 34% – # and % of Patients Showing Progressive Disease
——————————————————————
31 – Evaluable Patients: Special exception (SE)
�
5 / 16% – # and % of Patients Showing Complete Response
2 / 6% – # and % of Patients Showing Partial Response
16 / 52% – # and % of Patients Showing Stable Disease
8 / 26% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:
�
4. 10/2004 (AT/RT of CNS)
�
NEURO-ONCOLOGY
�
BT-14
�
CHILDREN WITH RHABDOID TUMOR OF THE CENTRAL NERVOUS SYSTEM
�
Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.
�
Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system
�
A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/1146.pdf
Neuro-Oncology. 2004; 6: 427
Volume 6 Issue 4 October 2004
Abstracts from the Eleventh International Symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16, 2004
�
10/2004 – Protocol – children with atypical teratoid / rhabdoid tumors (AT / RT) of the central nervous system
�
11 – Children Patients Accrued
8 – Evaluable Patients
(7 treated under Special Exception (SE))
�
2 / 25% – # and % of Patients Showing Complete Response
1 / 12.5% – # and % of Patients Showing Partial Response
1 / 12.5% – # and % of Patients Showing Stable Disease
4 / 50% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:
�
5. 10/2004
�
NEURO-ONCOLOGY
�
BT-12
�
CHILDREN WITH PRIMITIVE NEUROECTODERMAL TUMORS (PNET)
�
Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
�
Treatment of PRIMITIVE NEUROECTODERMAL TUMORS (PNET) with antineoplastons A10 and AS2-1 (ANP)
�
Preliminary results of phase II studies
http://www.burzynskiclinic.com/images/stories/Publications/1147.pdf
Neuro-Oncology. 2004; 6: 428
Volume 6 Issue 4 October 2004
Abstracts from the Eleventh International Symposium on Pediatric Neuro-Oncology
�
10/2004 – Protocol – PRIMITIVE NEUROECTODERMAL TUMORS (PNET)
�
17 – Patients Accrued
15 – Evaluable Patients
(12 months – 23 years / 6 – median age)
�
3 / 20% – # and % of Patients Showing Complete Response
2 / 13.4% – # and % of Patients Showing Partial Response
5 / 33.3% – # and % of Patients Showing Stable Disease
5 / 33.3% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:
�
17. 2004
�
DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)
�
Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M.
�
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma.
�
A Preliminary Report.
http://www.ncbi.nlm.nih.gov/pubmed/15563234
Drugs R&D 2004;5(6):315-326.
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf
�
incurable recurrent and progressive multicentric glioma
�
Pg. 320
�
3 – treated under Special Exception (SE) granted by the US FDA
�
Pgs. 317 and 320
�
7/31/1996 – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive multicentric glioma (MCG)
�
Pg. 317
�
BT-13
�
children with low-grade astrocytoma
�
BT-23
�
children with visual pathway gliomas

�
Pgs. 317 and 320-321
�
12 – Children Patients Accrued (Pgs. 315-316)
(9 months – 17 years / 9- median age)
(6 – male / 6 – females)
10 – Evaluable Patients (Pg. 315)
�
4 / 33% – # and % of Patients Showing Complete Response
3 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
1 / 9% – # and % of Patients Non-evaluable
——————————————————————
Pg. 325
�
Compare: Chamberlain and Grafe. [38]
�
1995 – Protocol – solitary recurrent chiasmatic hypothalamic gliomas treated with oral etoposide

�
14 – Patients Accrued
14 – Evaluable Patients
�
1 / 7% – # and % of Patients Showing Complete Response
4 / 29% – # and % of Patients Showing Partial Response
3 / 21% – # and % of Patients Showing Stable Disease
6 / 43% – # and % of Patients Showing Progressive Disease
�
Pg. 326
�
38. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995; 13: 2072-6
http://www.ncbi.nlm.nih.gov/pubmed/7636550/
J Clin Oncol. 1995 Aug;13(8):2072-6.
http://www.ncbi.nlm.nih.gov/m/pubmed/7636550/
Department of Neurosciences, University of California, San Diego, La Jolla, USA.
http://m.jco.ascopubs.org/content/13/8/2072.long
Arch Neurol. 1995 May;52(5):509-13.
http://www.ncbi.nlm.nih.gov/pubmed/7733847/
Department of Neurosciences, University of California-San Diego, USA.
http://www.ncbi.nlm.nih.gov/m/pubmed/7733847/
Arch Neurol. 1995;52(5):509-513. doi:10.1001/archneur.1995.00540290099024.
http://archneur.jamanetwork.com/Mobile/article.aspx?articleid=593460
——————————————————————
Compare: The Pediatric Oncology Group. [39]
�
10/2000 – Protocol – solitary progressive optic pathway tumors with carboplatin
�
50 – Patients Accrued
50 – Evaluable Patients
�
2 / 4% – # and % of Patients Showing Partial Response
37 / 74% – # and % of Patients Showing Stable Disease
11 / 22% – # and % of Patients Showing Progressive Disease
�
39. Mahoney DH, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-oncol 2000; 2: 213-20
http://www.ncbi.nlm.nih.gov/pubmed/11265230/
Neuro Oncol. 2000 Oct;2(4):213-20.
http://www.ncbi.nlm.nih.gov/m/pubmed/11265230/
Baylor College of Medicine, Houston, TX, USA.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920597/
�
http://neuro-oncology.oxfordjournals.org/content/2/4/213.full.pdf
======================================
2005 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77
(Integrative Cancer Therapies)
�
2005: Protocol – recurrent disease or high risk
�
13 – Patients Accrued
(1-11 – age / 5 years 11 months – median age)
13 – Evaluable Patients
�
3 / 23% – # and % of Patients Showing Complete Response
1 / 8% – # and % of Patients Showing Partial Response
4 / 31% – # and % of Patients Showing Stable Disease
5 / 38% – # and % of Patients Showing Progressive Disease
——————————————————————
(Updated 2007)
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
2005 – Protocol – incurable recurrent and progressive multicentric glioma
�
13 – Patients Accrued
�
3 / 23% – # and % of Patients Showing Complete Response
1 / 8% – # and % of Patients Showing Partial Response
4 / 31% – # and % of Patients Showing Stable Disease
5 / 38% – # and % of Patients Showing Progressive Disease
======================================
2006 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
(Integrative Cancer Therapies)
�
2006: Protocol – high-grade pathology (HBSG)
�
– Patients Accrued
18 – Evaluable Patients
�
2 / 11% – # and % of Patients Showing Complete Response
2 / 11% – # and % of Patients Showing Partial Response
7 / 39% – # and % of Patients Showing Stable Disease
7 / 39% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:
�
BT-03
�

�
BT-11
�
BRAIN STEM GLIOMA (BSG)
�
BT-18
�
6. MIXED GLIOMA
�
ADULT PATIENTS WITH MIXED GLIOMA
�
“mixed glioma”, a type of primary malignant brain tumor (PMBT)
�
BT-22
�
8. CHILDREN WITH PRIMARY MALIGNANT BRAIN TUMORS
�
CAN-01 (CAN-1)
�
PATIENTS WITH REFRACTORY MALIGNANCIES
�
19. 3/2006
�
Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive BRAINSTEM GLIOMA. Integrative Cancer Therapies 2006;5(1):40-47
http://www.ncbi.nlm.nih.gov/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
DOI: 10.1177/1534735405285380
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf
�
http://m.ict.sagepub.com/content/5/1/40.long?view=long&pmid=16484713
Pgs. 40-41
�
4 phase 2 trials
�
BRAINSTEM GLIOMA (BSG)
�
patients with inoperable tumor of high-grade pathology (HBSG)
glioblastoma
�
recurrent diffuse intrinsic glioblastomas and ANAPLASTIC ASTROCYTOMAs of brainstem
�
Pg. 43
�
BT-03 – 1 / female
BT-11 – 13 (8 males/5 females)
BT-18 – 1 / female
BT-22 – 2 / females
CAN-01 – 1 / female
�
Pg. 44
�
High-grade, recurrent, and progressive brainstem gliomas
�
Pgs. 40-42 and 44-45
�
7/12/1988 (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem high-grade pathology (HBSG)
�
18 – Evaluable Patients (Pgs. 40-43)
(8 males / 10 females / 2-42 / 10 – median age / Pgs. 42-43)
�
2 / 11% – # and % of Patients Showing Complete Response
2 / 11% – # and % of Patients Showing Partial Response
7 / 39% – # and % of Patients Showing Stable Disease
7 / 39% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:
�
BT-11
�
BRAIN STEM GLIOMA
�
8. 10/2006
�
Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V. Treatment of multicentric BRAINSTEM GLIOMAs with antineoplastons (ANP) A10 and AS2-1. Neuro-Oncology. 2006; 8:466.
http://www.burzynskiclinic.com/images/stories/Publications/2105.pdf
Volume 8 Issue 4 October 2006
Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO)
�
Brainstem gliomas and multicentric tumors (MBSG)
�
10/2006 – Protocol – Brainstem gliomas and multicentric tumors (MBSG)
�
19 – Evaluable Patients
3.9 – 40.8 years (9.2 – median age)
(90% less than 18 years old)
�
2 / 11% – # and % of Patients Showing Complete Response
1 / 5% – # and % of Patients Showing Partial Response
7 / 37% – # and % of Patients Showing Stable Disease
9 / 47% – # and % of Patients Showing Progressive Disease
======================================
2007
http://www.burzynskiclinic.com/images/stories/Publications/1252.pdf
2004 – Protocol – small group of patients with progressive LGA, ANP
60% – % of Patients Showing Complete Response
10% – % of Patients Showing Partial Response
——————————————————————
2004 – Protocol – low-grade astrocytoma in children
Burzynski [39] – Reference
Phase II d – d = Preliminary results – Study type
P – P = progressive tumor – Tumor type
(no. of pts) – pts = patients
ANP (10) – ANP = antineoplastons A10 and AS2-1 – Treatment
10 – Evaluable Patients {(78) = most in a study}
OS [%] – OS = overall survival
100% (1 yr) – 90% (3 yr) – Efficacy
93 mo – MST = MST = median survival time – {96 (1 y) next closest}
60% (6) – % and # of Patients Showing Complete Response {24 (11) next closest}
10% (1) – % and # of Patients Showing Partial Response {60% (9) best other study}
30% (3) – % and # of Patients Showing Stable Disease + MR = minor response {70% (14) best other study}
0% (0) – % and # of Patients Showing Progressive Disease {4% (2) next closest}
PFS (%)
90 (1 y) – 90 (3 y) – PFS = progression-free survival {100 (1 y) – 68 (3 y) best other study
——————————————————————
2004 – Protocol – diffuse, intrinsic brainstem glioma in children
Burzynski et al. [88] – Reference
Phase II – Study Type
(no. of pts) – pts = patients
RP (30) – RP = recurrent and progressive tumor – Tumor type
30 – Evaluable Patients
ANP – ANP = antineoplastons A10 and AS2-1 – Treatment – ANP
OS (%) – OS = overall survival
[2y; 5y]
46.7; 30 – Efficacy
MST (mo)
19.9 – MST = median survival time
27% (8) – % and # of Patients Showing Complete Response
20% (6) – % and # of Patients Showing Partial Response
23% (7) – % and # of Patients Showing Stable Disease
30% (9) – % and # of Patients Showing Progressive Disease
——————————————————————
Burzynski et al. [89] – Reference
Phase II – Study Type
(no. of pts) – pts = patients
RPS (10) – RPS = recurrent and progressive tumors in children aged <4y – Tumor type {(66) = most in a study}
ANP – ANP = antineoplastons A10 and AS2-1 – Treatment – ANP
OS (%) – OS = overall survival
[2y; 5y] – Efficacy
60; 20 {46.7 (30) = next best study}
MST (mo)
26.3 – MST = median survival time – {19.9 = next best study}
[% (no. )]
30% (3) – CR = complete response – {27% (8) = next best study}
[% (no. )]
0% (0) – PR = partial response – {56% (1) = next best}
[% (no. )]
40% (4) – SD = stable disease – {44% (25) = best}
[% (no. )]
30% (3) – PD = progressive disease – {23% (13) = best}
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:
�
BT-11
�
BRAIN STEM GLIOMA
�
9. 4/2007 (NDBSG)
�
Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs. Neuro-Oncology 2007; 9:206.
http://www.burzynskiclinic.com/images/stories/Publications/4021.pdf
Volume 9 Issue 2 April 2007
Abstracts from the Twelfth International Symposium on Pediatric Neuro-Oncology
�
4/2007 – Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG)
�
20 – Evaluable assessable children Patients
(3 months-20 years – age)
�
6 / 30% – # and % of Patients Showing Complete Response
2 / 10% – # and % of Patients Showing Partial Response
4 / 20% – # and % of Patients Showing Stable Disease
8 / 40% – # and % of Patients Showing Progressive Disease
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:
�
BT-11
�
BRAIN STEM GLIOMA
�
Special exception (SE)
�
13. 12/2009 (DBSG)
�
Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with BRAINSTEM GLIOMA. Protocol BC-BT-11. Neuro-Oncology 2009, 11:951.
http://www.burzynskiclinic.com/images/stories/Publications/8639.pdf
Volume 11 Issue 6 December 2009
Abstracts from the Third Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and the Sixth Meeting of the Asian Society for Neuro-Oncology (ASNO)
May 11-14, 2009
Yokohama, Japan
�
12/2009 – Protocol – BRAINSTEM GLIOMAs
�
40 – Patients Accrued
28 – Evaluable Patients
(23 children / 5 young adults)
�
5 / 18% – # and % of Patients Showing Complete Response
4 / 14% – # and % of Patients Showing Partial Response
12 / 43% – # and % of Patients Showing Stable Disease
7 / 25% – # and % of Patients Showing Progressive Disease
——————————————————————
Special exception (SE)
�
12/2009 – Protocol – BRAINSTEM GLIOMAs
�
52 – Evaluable Patients
(40 children / 12 young adults)
�
5 / 10% – # and % of Patients Showing Complete Response
2 / 4% – # and % of Patients Showing Partial Response
28 / 54% – # and % of Patients Showing Stable Disease
17 / 32% – # and % of Patients Showing Progressive Disease
——————————————————————
BT-11 and special exception (SE)
92% – diffuse intrinsic brainstem gliomas (DBSG)
�
Overall survival (OS) – 2 years:
42% – special exception (SE)
36% – BT-11
�
Overall survival (OS) – 5 years:
19% – special exception (SE)
25% – BT-11
======================================
Compare: standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al. 1999)
�
2% – % of Patients Showing Complete Response
31% – % of Patients Showing Partial Response
�
Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brain stem tumors: results of pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:959-964.
http://www.ncbi.nlm.nih.gov/pubmed/10192340/
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64.
http://www.ncbi.nlm.nih.gov/m/pubmed/10192340/
International Journal of Radiation Oncology*Biology*Physics
Volume 43, Issue 5, 15 March 1999, Pages 959–964
http://www.sciencedirect.com/science/article/pii/S036030169800501X
Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY, USA.
6/1992 – 10/1997
�
Overall survival (OS):
7% – 2 years
0% – 5 years
=====================================
COMBINED:
——————————————————————
Overall survival (OS) – 2 years:
——————————————————————
42% – antineoplastons: special exception (SE)
�
36% – antineoplastons: BT-11
�
7% – standard radiation therapy in combination with chemotherapy (RAT)
——————————————————————
Overall survival (OS) – 5 years:
——————————————————————
25% – antineoplastons: BT-11
�
19% – antineoplastons: special exception (SE)
�
0% – standard radiation therapy in combination with chemotherapy (RAT)
� � � � � � � � � � � � � � � � �
Break The Walls Down:
http://youtu.be/aAoJ1FY9kM8
——————————————————————
And “THAT’s The BOTTOM LINE”
Because Stone Cold Said So
http://youtu.be/v2KLaaykD5g
——————————————————————
IT’s GO TIME
Time To Play The Game:
http://youtu.be/xskJaEF-cuE
——————————————————————
Break The Walls Down:
http://youtu.be/JAG55VxlQeI
=====================================

On the 6th day, HE created WIKIPEDIA, and on the 7th, WikipedBiaS

Whilst I was giving Wikipedia the opportunity to prove to me that they actually believe in, and practice [[WP:NPOV]] (Wikipedia: Neutral Point Of View), I pointed out to Wikipedia that antineoplaston studies had taken place in Poland, South Korea, Russia, Egypt, Japan, Taiwan (Republic Of China), China, and the USA

Wikipedia, what’s your motivation?
https://stanislawrajmundburzynski.wordpress.com/2013/05/02/wikipedia-whats-your-motivation/
What was WikipedBiaS’ UN-BIASED, Neutral, rational wiki response?

> “What they mean is that nobody else is doing any meaningful work on it,
> which necessarily means that it’s not considered in the least
> promising.” Guy (Help!) 3:54 pm, 24 December 2012, Monday

I replied to this Guy’s’ G.I.G.O. (Garbage In, Garbage Out):

> Nobody else is doing meaningful work on it? Ignores independent research
> done in Poland, Russia, Korea, Egypt, Japan, & China which
> specifically reference SRB’s publications in their publications
> re antineoplastons & phenylacetylglutamine (PG); which is AS2-5, &
> includes phase III trials published in China & continued research being
> published in China 12/17/2012?

FACTS:

1. I pointed out to WikipedBiaS, a 12/17/2012 scientific publication re antineoplastons, which referenced Burzynski @ 22. (antineoplaston AS21)

2. 7 days after this scientific journal was published, WikipedBiaS’ “Guy (Help!’s) UN-BIASED, Neutral, rational wiki response on Monday, 12/24/2012 @ 3:54 pm, is to advise me; as if I just fell off the turnip truck he was born in:

“What they mean is that nobody else is doing any meaningful work on it, which necessarily means that it’s not considered in the least promising.” Guy (Help!) 3:54 pm, 24 December 2012, Monday

3. So, WikipedBiaS’ lackey, Guy (Help!), defines an event having been published 7 days ago (from 12/17/2012 to 12/24/2012) as:

…nobody else is doing any meaningful work on it…

>
See

http://en.wikipedia.org/w/index.php?title=Talk:Burzynski_Clinic&diff=next&oldid=529537854

to view this change.

I have an easy to remember, one (1) word, one (1) syllable, response for Jimmy (Jimbo) Donal Wales, Guy (Help!), and WikipedBiaS
http://youtu.be/iB2a0EZkDMk

BULLOCKS

http://redd.it/1etr0x
12/17/2012
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524164
CDA-2 (cell differentiation agent 2), a URINARY preparation
http://po.st/g71N8P
CDA-2 and its main component PHENYLACETYLGLUTAMINE (PG or PAG)
http://po.st/m2RcxL
Antineoplaston AS2-5 is PHENYLACETYLGLUTAMINE (PAG or PG)
http://redd.it/1dk974
Antineoplaston AS2-1 is a 4:1 mixture of phenylacetic acid (PA) and PHENYLACETYLGLUTAMINE (PAG or PG)
http://t.co/N7ErbunCV2
Antineoplastons AS2-5 and AS2-1 are derived from Antineoplaston A10
http://t.co/8NdDGWfgLL
BURZYNSKI Reference: 22.
http://t.co/EdMy4zPAz0
antineoplaston AS21

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117
BULLOCKS
http://t.co/FgdOUYPHW0

Burzynski: South Korea antineoplaston publications

1994 – (A-10) – Synthesis of Mannich bases of antineoplaston A10 and their antitumor activity
http://www.ncbi.nlm.nih.gov/m/pubmed/10319160
College of Pharmacy, National University, Kwangju, Korea
Arch Pharm Res 17(6):467-9 (1994)
http://link.springer.com/article/10.1007%2FBF02979127

http://www.springerlink.com/content/974026733070602v

4/1995 – Stability of antineoplaston A10 in aqueous solution
College of Pharmacy, Chonnam National University, Gwangju, Korea
Archives of Pharmacal Research
Volume 18, Issue 2 , pp 75-78
Springer DOI 10.1007/BF02979137
http://link.springer.com/article/10.1007%2FBF02979137?LI=true

http://www.springerlink.com/content/b94n2233t6435260

http://www.wikigenes.org/e/chem/e/56260.html

4/1998 – Synthesis of antineoplaston A10 analogs as potential antitumor agents
http://www.ncbi.nlm.nih.gov/m/pubmed/9875424
College of Pharmacy, Chonnam National University, Kwangju, Korea
Arch Pharm Res 21 (2):157-63 (1998)
Archives of Pharmacal Research, Springer
http://link.springer.com/article/10.1007%2FBF02974021

http://www.springerlink.com/content/861173134603u73